FDA clears Biogen Idec's hemophilia A drug

June 6, 2014 10:29 PM

5 0

NEW YORK (AP) — U.S. regulators on Friday approved Biogen Idec's drug Eloctate, a hemophilia A treatment that is designed to last longer than older drugs.

The Food and Drug Administration approved Eloctate for use in adults and children.

Also read: National Cancer Institute Says Researchers Didn’t Quickly Tell FDA After Two Deaths in a Lymphoma Study

Read more

To category page